• ISSN 16748301
  • CN 32-1810/R
Article Contents

Citation:

Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes

  • Received Date: 2017-08-01
    Accepted Date: 2017-09-21

    Fund Project: This study was fully supported by an internal funding from the Department of Anesthesiology & Perioperative Medicine to Dr. Henry Liu. A portion of the study was presented to Drexel Discovery Day as an abstract.

  • Congestive heart failure (CHF) is defined as a cardiac dysfunction leading to low cardiac output and inadequate tissue perfusion. Intravenous positive inotropes are used to increase myocardial contractility in hospitalized patients with advanced heart failure. Milrinone is a phosphodiesterase Ⅲ inhibitor and used most commonly for inotropic effect. The well-known PROMISE study investigated the effects of milrinone on mortality in patients with severe CHF, and concluded that long-term therapy with milrinone increased morbidity and mortality among patients with advanced CHF. Previous studies have suggested that phosphodiesterase inhibitors can have potential effects on inflammatory pathways. Hence, we hypothesized that milrinone may alter inflammatory gene expressions in cardiomyocytes, thus leading to adverse clinical outcomes. We used rat cardiomyocyte cell line H9C2 and studied the impact of exposing cardiomyocytes to milrinone (10 mmol/L) for 24 hours on inflammatory gene expressions. RNA extracted from cultured cardiomyocytes was used for whole rat genome gene expression assay (41,000 genes). The following changes in inflammatory response-related gene expressions were discovered. Genes with increased expressions included:THBS2 (+ 9.98), MMP2 (+ 3.47), DDIT3 (+ 2.39), and ADORA3 (+ 3.5). Genes with decreased expressions were:SPP1 (- 5.28) and CD14 (- 2.05). We found that the above mentioned gene expression changes seem to indicate that milrinone may hinder the inflammatory process which may potentially lead to adverse clinical outcomes. However, further in vivo and clinical investigations will be needed to illustrate the clinical relevance of these gene expression changes induced by milrinone.
  • 加载中
  • [1] Shipley JB, Hess ML. Inotropic therapy for the failing myocardium[J]. Clin Cardiol, 1995, 18(11):615-619.
    [2] Hunt SA, Abraham WT, Chin MH, et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults task force members[J]. JAC, 2009, 53(15):e1-e90.
    [3] Belletti A, Castro ML, Silvetti S, et al. The effect of inotropes and vasopressors on mortality:a meta-analysis of randomized clinical trials[J]. Br J Anaesth, 2015, 115(5):656-675.
    [4] Jaiswal A, Nguyen VQ, Le Jemtel TH, et al. Novel role of phosphodiesterase inhibitors in the management of end-stage heart failure[J]. World J Cardiol, 2016, 8(7):401-412.
    [5] Tang X, Liu P, Li R, et al. Milrinone for the treatment of acute heart failure after acute myocardial infarction:a systematic review and meta-analysis[J]. Basic Clin Pharmacol Toxicol, 2015, 117(3):186-194.
    [6] Zangrillo A, Biondi-Zoccai G, Ponschab M, et al. Milrinone and mortality in adult cardiac surgery:a meta-analysis[J]. J Cardiothorac Vasc Anesth, 2012, 26(1):70-77.
    [7] Packer M, Carver JR, Rodeheffer RJ, et al. Effect of oral milrinone on mortality in severe chronic heart failure[J]. N Engl J Med, 1991, 325(21):1468-1475.
    [8] Chanani NK, Cowan DB, Takeuchi K, et al. Differential effects of amrinone and milrinone upon myocardial inflammatory signaling[J]. Circulation, 2002, 106(12 Suppl 1):I284-I289.
    [9] Liu H, Sangkum L, Liu G, et al. Effects of epinephrine on angiogenesis-related gene expressions in cultured rat cardiomyocytes[J]. J Biomed Res, 2016, 30(5):380-385.
    [10] Chen S, Liu GL, Li MM, et al. Effects of epinephrine on inflammation-related gene expressions in cultured rat cardiomyocytes[J]. Transl Perioper Pain Med, 2017, 2(1):13-19.
    [11] Zhao F, Li B, Wei YZ, et al. MicroRNA-34a regulates high glucose-induced apoptosis in H9c2 cardiomyocytes[J]. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(6):834-839.
    [12] Merten KE, Jiang Y, Feng W, et al. Calcineurin activation is not necessary for doxorubicin-induced hypertrophy in H9c2 embryonic rat cardiac cells:involvement of the phosphoinositide 3-kinase-Akt pathway[J]. J Pharmacol Exp Ther, 2006, 319(2):934-940.
    [13] Hamid T, Xu Y, Ismahil MA, et al. TNF receptor signaling inhibits cardiomyogenic differentiation of cardiac stem cells and promotes a neuroadrenergic-like fate[J]. Am J PhysiolHear Circ Physiol, 2016, 311(5):H1189-H1201.
    [14] Abu El-Asrar AM, Nawaz MI, Ola MS, et al. Expression of thrombospondin-2 as a marker in proliferative diabetic retinopathy[J]. Acta Ophthalmol, 2013, 91(3):e169-e177.
    [15] Hanatani S, Izumiya Y, Takashio S, et al. Circulating thrombospondin-2 reflects disease severity and predicts outcome of heart failure with reduced ejection fraction[J]. Circ J, 2014, 78(4):903-910.
    [16] Frangogiannis NG, Ren G, Dewald O, et al. Critical role of endogenous thrombospondin-1 in preventing expansion of healing myocardial infarcts[J]. Circulation, 2005, 111(22):2935-2942.
    [17] Schroen B, Heymans S, Sharma U, et al. Thrombospondin-2 is essential for myocardial matrix integrity:increased expression identifies failure-prone cardiac hypertrophy[J]. Circ Res, 2004, 95(5):515-522.
    [18] Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling[J]. Nat Rev Mol Cell Biol, 2007, 8(3):221-233.
    [19] Hori Y, Kashimoto T, Yonezawa T, et al. Matrix metalloproteinase-2 stimulates collagen-I expression through phosphorylation of focal adhesion kinase in rat cardiac fibroblasts[J]. Am J Physiol Cell Physiol, 2012, 303(9):C947-C953.
    [20] Nepomnyashchikh LM, Lushnikova EL, Bakarev MA, et al. Immunohistochemical analysis of MMP-2 expression in the myocardium during the postinfarction period[J]. Bull Exp Biol Med, 2015, 159(4):505-510.
    [21] Gao L, Zheng YJ, Gu SS, et al. Degradation of cardiac myosin light chain kinase by matrix metalloproteinase-2 contributes to myocardial contractile dysfunction during ischemia/reperfusion[J]. J Mol Cell Cardiol, 2014, 77:102-112.
    [22] Libby P. Collagenases and cracks in the plaque[J]. J Clin Invest, 2013, 123(8):3201-3203.
    [23] Newby AC. Metalloproteinase production from macrophages- a perfect storm leading to atherosclerotic plaque rupture and myocardial infarction[J]. Exp Physiol, 2016, 101(11):1327- 1337.
    [24] Kostov K, Blazhev A, Atanasova M, et al. Serum concentrations of endothelin-1 and matrix metalloproteinases-2, -9 in prehypertensive and hypertensive patients with type 2 diabetes[J]. Int J Mol Sci, 2016, 17(8):1-13.
    [25] Jiang L, Zhang J, Monticone RE, et al. Calpain-1 regulation of matrix metalloproteinase 2 activity in vascular smooth muscle cells facilitates age-associated aortic wall calcification and fibrosis[J]. Hypertension, 2012, 60(5):1192-1199.
    [26] Qian J, Chen Z, Lin J, et al. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases[J]. Leuk Res, 2005, 29(12):1435- 1441.
    [27] Lin J, Wang YL, Qian J, et al. Aberrant methylation of DNAdamage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome[J]. Leuk Res, 2010, 34(8):991-994.
    [28] Xu Y, Chen Z, Zhang G, et al. HSP90B1 overexpression predicts poor prognosis in NSCLC patients[J]. Tumour Biol, 2016, 37(10):14321-14328.
    [29] Shneyvays V, Zinman T, Shainberg A. Analysis of calcium responses mediated by the A3 adenosine receptor in cultured newborn rat cardiac myocytes[J]. Cell Calcium, 2004, 36(5):387-396.
    [30] Galal A, El-Bakly WM, Al Haleem EN, et al. Selective A3 adenosine receptor agonist protects against doxorubicininduced cardiotoxicity[J]. Cancer Chemother Pharmacol, 2016, 77(2):309-322.
    [31] Lu Z, Fassett J, Xu X, et al. Adenosine A3 receptor deficiency exerts unanticipated protective effects on the pressure overloaded left ventricle[J]. Circulation, 2008, 118(17):1713-1721.
    [32] Kahles F, Findeisen HM, Bruemmer D. Osteopontin:A novel regulator at the cross roads of inflammation, obesity and diabetes[J]. Mol Metab, 2014, 3(4):384-393.
    [33] Meng C, Liu Z, Liu GL, et al. Ketamine promotes inflammation through increasing TLR4 expression in RAW264.7 cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(3):419-425.
    [34] Lund H, Boysen P, Åkesson CP, et al. Transient migration of large numbers of CD14(++) CD16(+) monocytes to the draining lymph node after onset of inflammation[J]. Front Immunol, 2016, 7:322.
    [35] Krasity BC, Troll JV, Lehnert EM, et al. Structural and functional features of a developmentally regulated lipopolysaccharide-binding protein[J]. MBio, 2015, 6(5):e01193-15.
    [36] Friedrich K, Smit M, Brune M, et al. CD14 is associated with biliary stricture formation[J]. Hepatology, 2016, 64(3):843- 852.
    [37] Guillou C, Fréret M, Fondard E, et al. Soluble alpha-enolase activates monocytes by CD14-dependent TLR4 signalling pathway and exhibits a dual function[J]. Sci Rep, 2016, 6:23796.
  • 加载中

Article Metrics

Article views(200) PDF downloads(5) Cited by()

Related
Proportional views
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Effects of milrinone on inflammatory response-related gene expressions in cultured rat cardiomyocytes

  • 1 Department of Anesthesiology & Perioperative Medicine, Drexel University College of Medicine, Hahnemann University Hospital, Philadelphia, PA 19102, USA;
  • 2 Department of Anesthesiology, Huangshi Central Hospital, Huangshi, Hubei 435002, China;
  • 3 Division of Genomic Diagnostics, Department of Pathology & Laboratory Medicine, Children's Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA
Fund Project:  This study was fully supported by an internal funding from the Department of Anesthesiology & Perioperative Medicine to Dr. Henry Liu. A portion of the study was presented to Drexel Discovery Day as an abstract.

Abstract: Congestive heart failure (CHF) is defined as a cardiac dysfunction leading to low cardiac output and inadequate tissue perfusion. Intravenous positive inotropes are used to increase myocardial contractility in hospitalized patients with advanced heart failure. Milrinone is a phosphodiesterase Ⅲ inhibitor and used most commonly for inotropic effect. The well-known PROMISE study investigated the effects of milrinone on mortality in patients with severe CHF, and concluded that long-term therapy with milrinone increased morbidity and mortality among patients with advanced CHF. Previous studies have suggested that phosphodiesterase inhibitors can have potential effects on inflammatory pathways. Hence, we hypothesized that milrinone may alter inflammatory gene expressions in cardiomyocytes, thus leading to adverse clinical outcomes. We used rat cardiomyocyte cell line H9C2 and studied the impact of exposing cardiomyocytes to milrinone (10 mmol/L) for 24 hours on inflammatory gene expressions. RNA extracted from cultured cardiomyocytes was used for whole rat genome gene expression assay (41,000 genes). The following changes in inflammatory response-related gene expressions were discovered. Genes with increased expressions included:THBS2 (+ 9.98), MMP2 (+ 3.47), DDIT3 (+ 2.39), and ADORA3 (+ 3.5). Genes with decreased expressions were:SPP1 (- 5.28) and CD14 (- 2.05). We found that the above mentioned gene expression changes seem to indicate that milrinone may hinder the inflammatory process which may potentially lead to adverse clinical outcomes. However, further in vivo and clinical investigations will be needed to illustrate the clinical relevance of these gene expression changes induced by milrinone.

    HTML

Reference (37)

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return